Emergent Says Treatment For Hospitalized Covid Patients Shows No Benefit

Emergent BioSolutions provided an update on the evaluation of its investigational SARS-CoV-2 immune globulin intravenous, or COVID-HIG, for the treatment of hospitalized patients with COVID-19.